SCHEMBL282793

SCHEMBL282793

O=C(Oc1c(I)cc(O)cc1I)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 2/20 0.49
▸ ESR2 Q92731 2/20 0.49
▸ MAPT P10636 5/20 0.46
▸ KMT2A Q03164 5/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ LMNA P02545 4/20 0.45
▸ F2 P00734 1/20 0.45
▸ GAA P10253 3/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.42
▸ JAK2 O60674 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ SENP1 Q9P0U3 1/20 0.42
▸ PARP10 Q53GL7 1/20 0.42
▸ NSD2 O96028 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9522865 0.86 KMT2A (0.54) MAPTKMT2AMEN1TDP1LMNA
SCHEMBL27713146 0.85 SENP1 (0.51) ESR1ESR2MAPTKMT2AMEN1
Phenol SCHEMBL27713147 0.84 KMT2A (0.45) ESR1ESR2MAPTKMT2AMEN1
SCHEMBL10611304 0.81 ESR1 (0.51) ESR1ESR2MAPTKMT2AMEN1
SCHEMBL29346616 0.79 KMT2A (0.47) ESR1ESR2MAPTKMT2AMEN1
SCHEMBL21500876 0.79 SENP1 (0.54) ESR1ESR2MAPTKMT2AMEN1
SCHEMBL283401 0.79 ESR1 (0.49) ESR1ESR2MAPTKMT2AMEN1
SCHEMBL5551848 0.78 LMNA (0.64) ESR1ESR2MAPTKMT2AMEN1
SCHEMBL21500814 0.76 CA12 (0.42) ESR1POLBSENP1NSD2SLC2A1
SCHEMBL21500817 0.76 CA12 (0.47) ESR1POLBSENP1NSD2SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1689383-B1 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS INC (US) 2012-10-31 — — EP disclosed
EP-2428516-A1 Novel phosphorus-containing thyromimetics Metabasis Therapeutics, Inc. (US) 2012-03-14 — — EP disclosed
US-7829552-B2 Phosphorus-containing thyromimetics METABASIS THERAPEUTICS, INC. (US) 2010-11-09 — — US disclosed
US-20100081634-A1 Novel Phosphorus-Containing Thyromimetics METABASIS THERAPEUTICS, INC. (US) 2010-04-01 — — US disclosed
US-20090118236-A1 Novel Phosphorus-Containing Thyromimetics CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2009-05-07 — — US disclosed
US-7514419-B2 Phosphorus-containing thyromimetics METABASIS THERAPEUTICS, INC. (US) 2009-04-07 — — US disclosed
EP-1689383-A4 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS INC (US) 2009-02-18 — — EP disclosed
US-20090028925-A1 Novel Phosphinic Acid-Containing Thyromimetics METABASIS THERAPEUTICS, INC. 2009-01-29 — — US disclosed
EP-1891080-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS Metabasis Therapeutics, Inc. (US) 2008-02-27 — — EP disclosed
EP-1890768-A2 NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS Metabasis Therapeutics, Inc. (US) 2008-02-27 — — EP disclosed
WO-2006128056-A2 NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2006-11-30 — — WO disclosed
WO-2006128055-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2006-11-30 — — WO disclosed
EP-1689383-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS Metabasis Therapeutics, Inc. (US) 2006-08-16 — — EP disclosed
US-20060046980-A1 Novel phosphorus-containing thyromimetics METABASIS THERAPEUTICS, INC. 2006-03-02 — — US disclosed
WO-2005051298-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2005-06-09 — — WO disclosed
US-5273885-A Using a polyiodothyronine analog of a phenyl compound containing a hydroxyl group ortho to an iodine SYNTEX (U.S.A.) INC. (US) 1993-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081634-A1 Novel Phosphorus-Containing Thyromimetics PYGL, THRA, THOP1 ESR1 1256/4885ESR2 2127/4885MAPT 3512/4885
US-20060046980-A1 Novel phosphorus-containing thyromimetics PYGL, THRA, THOP1 ESR1 1256/4885ESR2 2127/4885MAPT 3512/4885
US-20090118236-A1 Novel Phosphorus-Containing Thyromimetics THRA, PYGL, THRB ESR1 1422/4885ESR2 2198/4885MAPT 3885/4885
US-20090028925-A1 Novel Phosphinic Acid-Containing Thyromimetics PYGL, PHOSPHO1, LIPE ESR1 1935/4885ESR2 2821/4885MAPT 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback